(BNTX) BioNTech SE BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BNTX) BioNTech SE Complete Analysis Pack
Actionable Strategy Starts Here
This BioNTech SE BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Autogene cevumeran (BNT122), Phase 2
Autogene cevumeran (BNT122) is BioNTech SE’s personalized neoantigen vaccine, in Phase 2 for first-line melanoma and Phase 1a/1b in solid tumors, so it sits in a high-value oncology niche with strong unmet need. Melanoma alone had about 100,000 new cases worldwide in 2022, and the cancer vaccine market is still early but expanding fast. If BioNTech converts even part of this pipeline, BNT122 could become one of its clearest long-term growth drivers.
BNT111 FixVac melanoma program, Phase 2
BNT111 is BioNTech SE's Phase 2 FixVac candidate for advanced melanoma, a cancer where immunotherapy still drives premium pricing and strong demand. BioNTech positions it as a flagship cancer-vaccine asset because melanoma remains one of the clearest settings for checkpoint and vaccine combo use. In BioNTech SE's BCG Matrix, it fits Stars: high-growth potential with meaningful clinical upside.
BNT113 HPV-positive head and neck cancer, Phase 2
BNT113 is in Phase 2 for HPV-positive head and neck cancer, a subgroup that makes up about 25% to 35% of head and neck squamous cell carcinomas and remains poorly served. The overall disease burden is large, with more than 900,000 new head and neck cancer cases worldwide each year. A clean positive readout would be a strong catalyst for BioNTech SE's oncology pipeline and its BCG "Star" case.
BNT321 pancreatic cancer antibody, Phase 2
BNT321 is a Phase 2 IgG1 monoclonal antibody for pancreatic cancer, a market with very high unmet need and strong pricing power. Pancreatic cancer causes about 5% of global cancer deaths and has a 5-year survival near 13%, so even modest efficacy could matter. This fits BioNTech SE’s push into larger oncology markets.
- Phase 2 asset with high upside
- Targets a hard-to-treat cancer
- Supports oncology expansion
BNT211 CAR-T solid tumor program
BNT211 is BioNTech SE’s CAR-T program for solid tumors, and it fits the "Star" slot because it sits in a fast-growing cell-therapy market with heavy pharma spending. BioNTech is using this asset to move beyond its vaccine base into advanced oncology, where the addressable market is still expanding and early clinical wins can scale fast.
- Solid tumor CAR-T is a high-growth niche.
- BioNTech is broadening beyond vaccines.
- Pipeline optionality can raise long-term value.
BioNTech’s Oncology Stars Could Fuel Its Next Growth Wave
BNT122, BNT111, BNT113, BNT321, and BNT211 are BioNTech SE Stars because they sit in fast-growing oncology niches with Phase 1/2 upside and clear unmet need. Melanoma had about 100,000 new cases in 2022, HPV-positive head and neck cancer is 25% to 35% of cases, and pancreatic cancer has about 13% 5-year survival. These assets can drive BioNTech SE’s next growth leg if trials keep reading well.
| Asset | Stage | Star case |
|---|---|---|
| BNT122 | Phase 2 | Melanoma vaccine upside |
| BNT111 | Phase 2 | Advanced melanoma |
| BNT113 | Phase 2 | HPV-positive head and neck |
| BNT321 | Phase 2 | Pancreatic cancer |
| BNT211 | CAR-T | Solid tumor growth |
What is included in the product
Detailed Word Document
BioNTech SE BCG Matrix maps its portfolio to spot stars, cash cows, question marks, and dogs for smart capital allocation.
Editable Excel File
BioNTech SE BCG Matrix for a quick, clear view of portfolio priorities and growth pain points
Reference Sources
Builds trust and speeds decisions by tracing BioNTech SE claims to credible, clearly cited sources.
Cash Cows
Comirnaty COVID-19 vaccine franchise
Comirnaty stayed BioNTech SE’s main cash engine in FY2025, even as COVID-19 demand cooled well below the pandemic peak. The Pfizer-partnered mRNA vaccine still led booster sales and remains the clearest cash-generating asset in the portfolio, after BioNTech reported €2.75 billion revenue in 2024.
Pfizer commercialization partnership
BioNTech’s Pfizer deal still acts as a cash cow: BioNTech kept 2025 revenue guidance at €1.7 billion to €2.2 billion, with most value tied to Comirnaty sales and shared commercialization. Shared R&D, manufacturing, and selling costs lower BioNTech’s standalone burn, and the cash helps fund oncology and other pipeline programs. In short, it is a steady funding engine, not a growth drag.
Seasonal booster sales channel
COVID-19 booster sales still act as a cash cow in 2025: BioNTech’s COVID-19 product revenues were €1.5 billion in 2024, showing a mature but recurring stream far below pandemic peaks. The channel stays low-growth, but BioNTech keeps an edge through its Pfizer-linked distribution network and strong brand recall in seasonal vaccination cycles.
Manufacturing and supply capacity for mRNA vaccines
BioNTech’s mRNA vaccine plants are a mature cash engine: they were built for large-scale output, so approved products can be supplied with lower incremental cost than building new capacity. In BioNTech SE’s latest reported year, cash and cash equivalents were about €12.8 billion, and the company still used that industrial base to support commercial vaccine supply rather than chase fast unit growth.
- Built capacity lowers supply cost.
- Approved products drive steady cash flow.
- Mature asset, not a growth bet.
- Supports BioNTech’s strong liquidity.
Partner-funded collaboration revenue
BioNTech SE’s partner-funded collaboration revenue is a clear Cash Cow: Genentech, Sanofi, Genmab, Regeneron, and others can pay upfront fees, milestones, and research support that help fund R&D without new equity. This income is non-dilutive and can offset heavy pipeline spending while BioNTech keeps advancing oncology and infectious-disease programs.
- Upfront, milestone, research cash
- Supports R&D without dilution
- Multiple active pharma partners
In 2025, this stream stayed important as BioNTech kept investing from a strong liquidity base of about €17.4 billion in cash, cash equivalents, and securities at 31 Dec 2024.
BioNTech’s Cash Cows Still Power Growth
BioNTech SE’s Cash Cows are still Comirnaty and partner-funded collaboration revenue. BioNTech SE held 2025 revenue guidance at €1.7 billion to €2.2 billion, after €2.75 billion in 2024 revenue and €1.5 billion in COVID-19 product revenue, while €17.4 billion in cash, cash equivalents, and securities at 31 Dec 2024 supports the pipeline.
| Cash Cow | Key data |
|---|---|
| Comirnaty | €1.5 billion COVID revenue |
| Liquidity | €17.4 billion cash and securities |
Full Version Awaits
BioNTech SE Reference Sources
The BioNTech SE BCG Matrix preview you see here is the exact document you’ll receive after purchase. There are no hidden pages, watermarks, or demo sections—just the full, ready-to-use report. It’s formatted for clear strategy review, investor analysis, and easy presentation. Once purchased, the same file is instantly available for download.
Dogs
Standalone primary-series COVID-19 vaccine demand
Standalone primary-series COVID-19 vaccine demand is a Dog for BioNTech SE: by 2025, new-priming volumes are far below the 2021-2022 peak, when more than 11 billion doses were administered worldwide. The market is now low-growth and mostly limited to rare unvaccinated or special-risk cases, so upside is thin. BioNTech's COVID-19 revenue base has shifted to boosters and updated shots, not fresh primary series starts.
Legacy pandemic inventory and supply build-out
BioNTech SE’s pandemic-era supply base was built for emergency demand, but 2025 sales are guided at €1.7 billion to €2.2 billion, far below peak COVID levels. That leaves older inventory and excess capacity with weak returns, since fixed plant and stock built for crisis use now sit in a lower-volume market. In BCG terms, this is a clear Dog: high carry cost, low growth, and little room to expand.
Non-core infectious-disease projects outside COVID and flu
BioNTech’s non-core infectious-disease projects stay small next to COVID and flu, with most still in early-stage testing and no clear near-term scale. The company spent €1.78 billion on R&D in 2024, so these programs still absorb cash while market share stays limited. That makes them a Dogs-style drag, not a profit engine.
Exploratory programs with no late-stage path
BioNTech SE’s exploratory projects sit in discovery or very early development, so they bring no commercial revenue and no proven market share. In 2025, these assets still looked like pure option value, not cash generators, which makes them weak candidates for large capital allocation versus later-stage oncology and mRNA programs.
That is the core Dogs case: high scientific risk, low visibility, and no clear path to scale. If a project has not moved beyond early data, it can absorb capital for years before any payback.
- No revenue yet
- No proven market position
- High burn, low certainty
Low-traction small-market initiatives
These low-traction small-market initiatives fit the dog bucket: in biotech, non-differentiated programs are hard to scale, and without strong clinical data they rarely win meaningful share. BioNTech SE should treat them as capital drags unless they show clear efficacy, safety, or partner demand.
- Low growth, low share
- Weak data limits adoption
- Hard to scale in biotech
- Best for pruning or partnering
BioNTech’s Dogs: Shrinking COVID Sales, High R&D Burn
BioNTech SE’s Dogs are its fading COVID-19 primary-series business and small early-stage non-core programs: both have low growth, weak share, and poor capital efficiency. 2025 COVID sales guidance of €1.7 billion to €2.2 billion is far below pandemic peak demand, while 2024 R&D was €1.78 billion, so these assets still consume cash. The core issue is simple: little scale, little pricing power, and limited near-term upside.
| Dog item | Latest data |
|---|---|
| COVID sales guidance | €1.7bn-€2.2bn, 2025 |
| R&D spend | €1.78bn, 2024 |
| Primary-series demand | Well below 2021-2022 peak |
Question Marks
BNT112 prostate cancer, Phase 1/2a
BNT112 is still in Phase 1/2a, so BioNTech SE has no commercial prostate cancer share yet. The market is big, with about 1.5 million new prostate cancer cases worldwide in 2022, but success is still uncertain because early-stage oncology assets face high attrition. For BioNTech SE, that makes BNT112 a question mark with upside, not a near-term cash driver.
BNT114 triple-negative breast cancer, Phase 1
BNT114 is still a Phase 1 program for triple-negative breast cancer, so it stays in BioNTech SE's question mark bucket. TNBC makes up about 10%–15% of breast cancers and remains a high-need area, with limited targeted options and strong clinical demand. But the asset needs stronger human data on safety, response, and durability before it can justify a higher BCG score.
BNT115 ovarian cancer, Phase 1
BNT115 is still in Phase 1 in ovarian cancer, a large but crowded market with global 2025 sales of about $4 billion and many active rivals. BioNTech’s share is still near zero, and the asset carries high clinical and regulatory risk. That makes it a clear Question Mark in the BCG matrix.
BNT116 non-small cell lung cancer, preclinical
BNT116 is still preclinical in non-small cell lung cancer, so BioNTech SE has no clinical proof of efficacy or market share yet. That said, NSCLC is a huge target: lung cancer caused about 2.48 million new cases and 1.82 million deaths globally in 2022, and NSCLC makes up about 85% of lung cancers, so the upside is real if trials work.
- Preclinical only, no human validation
- Huge NSCLC market, about 85% of lung cancers
- No current revenue or share
- High growth optionality, high failure risk
SAR441000, BNT141, and BNT142 solid tumor programs
SAR441000, BNT141, and BNT142 are still early Phase 1 solid-tumor bets, so they sit in the "question mark" box: high market upside, but no clear proof yet. Solid tumors make up about 90% of adult cancers, and global oncology sales were roughly $200 billion in 2025, so the prize is huge. BioNTech still needs clean response data, durability, and a clear edge over intratumoral rivals before these assets can move toward "star" status.
- Phase 1 only: no late-stage proof yet
- Solid tumors: biggest oncology growth pool
- Need differentiation to win share
- Clinical data will decide re-rating
BioNTech’s Early Pipeline: Big Upside, High Risk
BioNTech SE's Question Marks stay early and risky: BNT112, BNT114, BNT115, BNT116, SAR441000, BNT141, and BNT142 have little or no revenue, while most are Phase 1 or preclinical. The upside is large in prostate, TNBC, ovarian cancer, NSCLC, and solid tumors, but 2026 value still depends on human data, response durability, and clear differentiation.
| Asset | Stage | Status |
|---|---|---|
| BNT115 | Phase 1 | Ovarian cancer, $4B 2025 sales |
| BNT116 | Preclinical | NSCLC, 85% of lung cancers |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.